TARGETING THE ADENOSINE PATHWAY FOR ENHANCING CANCER THERAPY
Grant number: 1062580 | Funding period: 2014 - 2016
We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance the effectiveness of chemotherapy. These drugs are already known to be well-tolerated in humans and so have great potential for clinical development. We propose to determine the therapeutic response achieved with these drugs in combination with established cancer treatments involving radiotherapy and immune based therapies.
Related publications (3)
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4( )Foxp3(-) Cell-Mediated Modulation of CD103( ) Dendritic Cells
Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, Alexander J Davenport, Emma V Petley, Imran G House, Junyun Lai, Kevin Sek, Nicole Milenkovski, Liza B John, Sherly Mardiana, Clare Y Slaney, Joseph A Trapani, Sherene Loi, Michael H Kershaw, Nicole M Haynes, Phillip K Darcy